Iterum Therapeutics (ITRM) EPS (Weighted Average and Diluted) (2020 - 2022)
Historic EPS (Weighted Average and Diluted) for Iterum Therapeutics (ITRM) over the last 3 years, with Q4 2022 value amounting to -$0.41.
- Iterum Therapeutics' EPS (Weighted Average and Diluted) fell 400000.0% to -$0.41 in Q4 2022 from the same period last year, while for Dec 2022 it was -$3.63, marking a year-over-year increase of 8781.47%. This contributed to the annual value of -$1.26 for FY2024, which is 5743.24% up from last year.
- Iterum Therapeutics' EPS (Weighted Average and Diluted) amounted to -$0.41 in Q4 2022, which was down 400000.0% from -$2.38 recorded in Q3 2022.
- In the past 5 years, Iterum Therapeutics' EPS (Weighted Average and Diluted) ranged from a high of $0.28 in Q3 2021 and a low of -$30.1 during Q4 2020
- In the last 3 years, Iterum Therapeutics' EPS (Weighted Average and Diluted) had a median value of -$0.48 in 2022 and averaged -$3.48.
- In the last 5 years, Iterum Therapeutics' EPS (Weighted Average and Diluted) soared by 14666.67% in 2021 and then plummeted by 400000.0% in 2022.
- Iterum Therapeutics' EPS (Weighted Average and Diluted) (Quarter) stood at -$30.1 in 2020, then skyrocketed by 99.97% to -$0.01 in 2021, then tumbled by 4000.0% to -$0.41 in 2022.
- Its EPS (Weighted Average and Diluted) stands at -$0.41 for Q4 2022, versus -$2.38 for Q3 2022 and -$0.55 for Q2 2022.